Tirzepatide
Tirzepatide has been studied in 2,061 papers since 2018: 226 trials and 480 observational studies in people, 93 in animals, 24 in cells, 1,013 reviews; 904 in the past year. It is an approved medicine. The newest paper, Nov 17, 2026: “Painful Non‐Diabetic Lumbosacral Radiculoplexus Neuropathy Following Tirzepatide Exposure: A Case Report”.
InterventionGLP-1 receptor agonistsApproved 2022
2,061 papers study it23 more mention it2,399 findingsUpdated
236 new papers in 30 daysSee all 1,798 papers on tirzepatide
At a glance
Tirzepatide lowers cardiovascular and kidney event risk versus dulaglutide in a human trial; independent labs report lower weight and HbA1c in humans. An observational study links it with more atrial fibrillation and myocardial infarction than semaglutide in non-diabetic adults with obesity and established atherosclerotic cardiovascular disease. Eli Lilly funds papers and sponsors trials; human papers declare developer ties.
2,399 findings in 1,044 papers from 2020 to 2026, 260 of them since April 2026
Independent labs found the same change in mice and people. 435 independent labs in 55 countries; 181 trials, 73 about aging, 4 with no results posted.
“sotagliflozin (OR 0.50; 0.36-0.69; p-score=0.87), and tirzepatide (OR 0.55; 95% CI 0.33-0.92; p-score=0.80), had lowest odds of HF”
119 of its findings point the other way.
- 435 independent labs in 55 countries
- 119 findings against
- 181 trials, 73 about aging, 4 with no results posted
- Funders: Eli Lilly and Company and others
- 749 of 1,952 findings with company ties
- 86 of 181 trials sponsored by its developers
- Human trial217
- Humans441
- Animals33
- Cells7
- In silico52
Studies in people
See all 218 studies of tirzepatide in people218 studies gave tirzepatide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
| Randomized trial16 weeks | 36 peopleType 2 diabetes | Diabetes, obesity & metabolism, Nov 8, 2026 | |
down: Decreases predicted 10-year cardiovascular disease riskDifference versus placebo −2.4 percentage points (95% CI −3.4 to −1.4); estimated HR 0.77 (95% CI 0.69–0.85) | Randomized trial112 weeks, including 52 weeks of randomized maintenance | 133 peopleadultsObesity or overweight without diabetes or baseline cardiovascular disease; continued maximum tolerated dose versus switching to placebo after 60 weeks of tirzepatide | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
down: Decreases total first and recurrent MACE-5 eventsrate ratio 0.87 (95% CI 0.80–0.95); 1,489 versus 1,696 total events | Randomized trial | 13,165 peopleBothmean 64.1 yearsMidlife adults; type 2 diabetes and established atherosclerotic cardiovascular disease | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Improves functional capacity down: Decreases body weight | Trial24 weeks | 120 peopleBoth61±9 yearsMidlife adults; Older adults; HFpEF with or without type 2 diabetes; in addition to guideline-directed therapy | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Decreases HbA1c-1.5% up: Increases serum albumin down: Decreases alanine transaminase | Treated cohort24 weeks | 88 peoplePatient cohorts | Endocrine journal, Sep 29, 2026 |
What did studies of tirzepatide find?
289Studies of tirzepatide measured 289 outcomes; the most studied are body weight (98 studies), HbA1c (37) and mortality (10).
Body weight
downin humans93downin mice3downin reviews2−17% mean weight loss, adherent patients
98 studies
Body weight
downin humans93downin mice3downin reviews2−17% mean weight loss, adherent patients
Tirzepatide decreases body weight in humans (HFpEF with or without type 2 diabetes; in addition to guideline-directed therapy).
“preliminary analyses demonstrated significant reductions in body weight and improvement in metabolic parameters and functional capacity”
Human trialHFpEF with or without type 2 diabetes; in addition to guideline-directed therapyup to 10 mg once weekly24 weeks64% womensn = 120
ESC Congress 2026 abstract
Tirzepatide decreases body weight in humans (single patient, dose escalation to 15 mg weekly) (<5% weight loss).
“achieved minimal weight loss (<5%) despite tirzepatide dose escalation to 15 mg weekly over 6 months”
Human trialsingle patient, dose escalation to 15 mg weekly15 mg weekly6 monthsmalesn = 1
Tirzepatide non-response with subsequent semaglutide response in class 2 obesity
JCEM case reports
Tirzepatide decreases body weight in humans.
“Participants treated with tirzepatide experienced greater reductions in BW and systolic blood pressure (SBP) compared with placebo, regardless of age subgroup, in each study.”
Human trial52 weeks
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Tirzepatide decreases body weight in adults with early uncontrolled T2D.
“tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y”
Human trialin adults with early uncontrolled T2D2 y
Annals of internal medicine
Tirzepatide decreases body weight in humans (compared with placebo) (-19.28% (95% CI -20.39% to -18.16%) versus placebo).
“followed by tirzepatide (-19.28%, -20.39% to -18.16%)”
Human trialcompared with placebo
BMJ medicine
Tirzepatide decreases body weight in humans (compared with semaglutide, after metabolic bariatric surgery) (mean difference 4.23% in favor of tirzepatide at 6 months).
“At 6 months, a mean difference in total weight loss of 4.23% was presented in favor of tirzepatide as compared to semaglutide.”
Human trialcompared with semaglutide, after metabolic bariatric surgery6 months
Frontiers in endocrinology
Tirzepatide decreases body weight in humans (clinically meaningful (no value stated)).
“Tirzepatide treatment was associated with clinically meaningful weight reduction”
Human trial
Diabetes, obesity & metabolism
Tirzepatide decreases body weight in humans (-12.5 kg (-14%) from baseline).
“Tirzepatide treatment resulted in a mean weight reduction of 12.5 kg (14%) of baseline weight”
Human trial22 weeks
Changes in Body Composition During and After Weight Loss with Tirzepatide
ADA Scientific Sessions 2026 abstract
Tirzepatide decreases body weight in humans (-14.6% (95% CI -15.5 to -13.8)).
“Mean weight loss was −5.3% (95% CI −5.6 to −4.9) with liraglutide, −12.0% (−12.4 to −11.5) with semaglutide, and −14.6% (−15.5 to −13.8) with tirzepatide”
Human trial15 mg once weekly
ADA Scientific Sessions 2026 abstract
Tirzepatide decreases body weight in humans (severe obstructive sleep apnea and morbid obesity) (-14 kg (-10.4%)).
“The patient achieved a 14 kg weight reduction (10.4% total body weight loss).”
Human trialsevere obstructive sleep apnea and morbid obesity2.5 mg weekly titrated to 5.0 mg weeklyapproximately 19 weeks and 4 daysmalesn = 1
Journal of Diabesity
All 100Fewer
HbA1c
downin humans37−1.5% to −0.6%
37 studies
HbA1c
downin humans37−1.5% to −0.6%
Tirzepatide decreases HbA1c in humans (unadjusted indirect comparison with semaglutide) (-0.10% vs semaglutide [-0.15, -0.05]).
“HbA1c(-0.08% [-0.13,-0.03], -0.10% [-0.15, -0.05])”
Human trialunadjusted indirect comparison with semaglutide15 mg/week
International journal of obesity (2005)
Tirzepatide decreases HbA1c in adults with early uncontrolled T2D.
“tirzepatide vs. intensified conventional care reduced HbA1c levels and weight at 2 y”
Human trialin adults with early uncontrolled T2D2 y
Annals of internal medicine
Tirzepatide decreases HbA1c in a patient with severe hypertriglyceridemia and type 2 diabetes (to 5.5% from 7.0%).
“HbA1c improved to 5.5%”
Human trialin a patient with severe hypertriglyceridemia and type 2 diabetesfemalesn = 1
Cardiovascular diabetology. Endocrinology reports
Tirzepatide decreases HbA1c in humans (compared with dulaglutide) (-2.18% (TZP) vs -1.28% (dula) at six months).
“At six months HbA1c was reduced more with TZP than on dula (-2.18%, -1.28%, p<0.001)”
Human trialcompared with dulaglutideup to 15 mg/weeksix monthsn = 449
ADA Scientific Sessions 2026 abstract
Tirzepatide decreases HbA1c in humans (switch from dulaglutide, across prespecified baseline subgroups).
“Reductions in HbA1c and body weight at week 40 were significant and consistently greater with tirzepatide across all prespecified baseline subgroups.”
Human trialswitch from dulaglutide, across prespecified baseline subgroupsweek 40
BMJ open diabetes research & care
Tirzepatide decreases HbA1c in humans (-0.77% (95% CI −0.98 to −0.56)).
“At week 40, the estimated treatment difference of tirzepatide compared with dulaglutide was −0.77% (95% CI −0.98 to −0.56, p<0.001) for HbA1c and −6.9 kg (95% CI−8.3 to −5.5, p<0.001) for body weight.”
Human trial40-week treatment periodn = 282
BMJ open diabetes research & care
Tirzepatide decreases HbA1c in humans (tirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses) (MD 0.33%; 95% CI 0.20, 0.46).
“tirzepatide was also more effective than semaglutide in reducing HbA1c (MD 0.33%; 95% CI: 0.20, 0.46)”
Human trialtirzepatide 15 mg versus semaglutide 2.4 mg at maximum doses15 mg versus 2.4 mg
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Journal of diabetes
Tirzepatide decreases HbA1c in humans (real-world pre-post treatment cohort).
“The glucometabolic profile improved consistently, with declines in fasting glucose, insulin, HbA1c, and triglycerides, alongside higher HDL-c.”
Human trialreal-world pre-post treatment cohort2.5 mg/week for 1 month, then 5.0 mg/weekmedian of 3 monthsn = 53
Frontiers in endocrinology
Tirzepatide is linked with lower HbA1c in humans (-1.5%).
“HbA1c levels and BMI decreased over 24 weeks after initiation of low-dose tirzepatide (HbA1c, -1.5%; BMI, -1.5 kg/m 2 ; both p < 0.001).”
Humansaverage 4.5 ± 1.0 mg/week24 weeksn = 88
Endocrine journal
Tirzepatide is linked with lower HbA1c in humans (combined with a standardized low-carbohydrate diet and tailored physical activity) (5.5 ± 0.4% to 5.2 ± 0.1%).
“Metabolic parameters were also improved, including HbA1c (from 5.5 ± 0.4% to 5.2 ± 0.1%, p = 0.007)”
Humanscombined with a standardized low-carbohydrate diet and tailored physical activityinitiated at 2.5 mg once weekly, increased to 5 mg; mean 5.32 mg24 weeksn = 122
Journal of diabetes and its complications
All 38Fewer
Mortality
downin humans6no changein humans4HR 0.6–0.99
10 studies
Mortality
downin humans6no changein humans4HR 0.6–0.99
Tirzepatide decreases mortality in humans (Type 2 diabetes and monovascular cardiovascular disease; compared with dulaglutide) (HR 0.86 (95% CI 0.75–0.99), p=0.03).
“Risk of all-cause death was reduced on tirzepatide in both monovascular (HR=0.86 [0.75, 0.99], p=0.03) and polyvascular (HR=0.78 [0.64, 0.95], p=0.02) groups”
Human trialType 2 diabetes and monovascular cardiovascular disease; compared with dulaglutiden = 10,309
AHA Scientific Sessions 2026 abstract
Tirzepatide decreases mortality in humans (versus placebo in type 2 diabetes) (OR 0.72, 95% CI 0.64-0.82).
“Tirzepatide (0.72, 0.64-0.82), SGLT2i (0.85, 0.80-0.91) and GLP1RA (0.85, 0.80-0.91) were associated with a significantly reduced mortality versus placebo”
Human trialversus placebo in type 2 diabetesat least 40 weeks
Diabetes, obesity & metabolism
Tirzepatide showed no clear effect on mortality in humans (odds ratio 1.02 (95% CI 0.57 to 1.81)).
“Beta-binomial regression showed no evidence of a difference when assessing all-cause mortality (odds ratio 1.02, 95% CI 0.57 to 1.81; p = 0.95”
Human trialplacebo-controlled trials in patients at increased risk of cardiovascular events; 21 trials
BMC medicine
Tirzepatide was not clearly linked with mortality in humans (Type 2 diabetes and heart failure with LVEF ≤50%; compared with GLP-1 receptor agonists) (4.3% vs 4.7%).
“Mortality was similar (4.3% vs 4.7%; p=0.736)”
HumansType 2 diabetes and heart failure with LVEF ≤50%; compared with GLP-1 receptor agonists365 days
AHA Scientific Sessions 2026 abstract
Tirzepatide was not clearly linked with mortality in humans (HR 0.99 [95% CI 0.81–1.21]; IR 20.5 vs. 19.5 per 1,000 person-years).
“Rates of all-cause mortality between the exposure groups were similar”
HumansAdults with heart failure with preserved ejection fraction and type 2 diabetes; compared with semaglutideOnce weeklyMedian follow-up of 5.1 months54% womensn = 37,183
Diabetes, obesity, and cardiometabolic CARE
Tirzepatide was not clearly linked with mortality in humans (compared with semaglutide in a new-user active-comparator cohort).
“No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.”
Humanscompared with semaglutide in a new-user active-comparator cohort12 monthsn = 35,336
Diabetes, obesity & metabolism
Tirzepatide is linked with lower mortality in humans (versus dulaglutide initiators) (HR 0.60, 95% CI 0.43-0.83).
“which seemed to be driven by lower all-cause mortality among tirzepatide versus dulaglutide initiators (HR 0.60 [95% CI 0.43-0.83])”
Humansversus dulaglutide initiators
Diabetes care
Tirzepatide is linked with lower mortality in humans (obese patients with OSA treated with PAP) (RR:0.12; 95% CI:0.10-0.14, NNT=6).
“lower mortality at 1 year (RR:0.14; 95% CI:0.12-0.17, NNT=9) and 3 years (RR:0.12; 95% CI:0.10-0.14, NNT=6).”
Humansobese patients with OSA treated with PAP3 years
medRxivPreprint
Tirzepatide decreases mortality in humans (type 2 diabetes; compared with dulaglutide; driven by the cardiovascular outcomes trial) (RR 0.85; CI 0.76 to 0.94).
“All-cause mortality was lower with tirzepatide (RR 0.85; CI 0.76 to 0.94), driven by the cardiovascular outcomes trial.”
Reviewtype 2 diabetes; compared with dulaglutide; driven by the cardiovascular outcomes trial
ESC Congress 2026 abstract
Tirzepatide decreases mortality in humans (subgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists) (HR 0.85, 95% CI 0.76-0.94).
“In exploratory subgroup analyses, patients with type 2 diabetes showed lower estimated risks of all-cause mortality (HR 0.85, 95% CI 0.76-0.94)”
Reviewsubgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists
Diabetes, obesity & metabolism
Body weight
downin humans8upin humans1
9 studies
Body weight
downin humans8upin humans1
Tirzepatide decreases body weight in humans (unadjusted indirect comparison with semaglutide 2.4 mg/week) (-6.50 kg vs semaglutide [-8.03, -4.97]).
“tirzepatide 10 and 15 mg demonstrated statistically significant improvements versus semaglutide in weight reduction (-5.10 kg [-6.63, - 3.57], -6.50 kg [-8.03,-4.97])”
Human trialunadjusted indirect comparison with semaglutide 2.4 mg/week15 mg/week
International journal of obesity (2005)
Tirzepatide decreases body weight in humans (−6.50 kg [−8.03,−4.97]).
“For efficacy estimand unadjusted ITCs, tirzepatide 10 and 15 mg demonstrated statistically significant improvements versus semaglutide in weight reduction (−5.10 kg [−6.63, − 3.57], −6.50 kg [−8.03,−4.97”
Human trialWeek 72 SURMOUNT-1, Week 68 STEP 1
International journal of obesity (2005)
Tirzepatide decreases body weight in humans across baseline subgroups.
“improvements were observed in body weight, systolic blood pressure, and sleep apnea-specific hypoxic burden across baseline subgroups”
Human trialacross baseline subgroupsmaximum tolerated dose (10 mg or 15 mg)52 weeks
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Tirzepatide decreases body weight in humans (combined with low energy ketogenic therapy or low calorie diet).
“Both groups achieved comparable reductions in BW after 12 weeks.”
Human trialcombined with low energy ketogenic therapy or low calorie diet12 weeks
Nutrients
Tirzepatide decreases body weight in humans (−10.2% ± 2.5 vs −9.8% ± 2.9).
“As shown in, after 12 weeks of treatment, both groups exhibited significant reductions in body weight.”
Human trial12 weeksn = 60
Nutrients
Tirzepatide is linked with lower body weight in a patient with obesity and cardiometabolic comorbidities (-27.8% (126 kg to 91 kg)).
“After 15 months of therapy, body weight decreased to 91 kg (-27.8%)”
Humansin a patient with obesity and cardiometabolic comorbidities12.5 mg once weekly15 months
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Meditsinskiy sovet = Medical Council
Tirzepatide is linked with lower body weight in humans (median total body weight loss 12.6%).
“At 12 months, median total body weight loss (TBWL) was 12.6%.”
Humans12 months
Journal of the Endocrine Society
Tirzepatide is linked with lower body weight in humans (patients with obesity) (-18.04 kg (-17.21%)).
“At this visit, the mean body weight reduction was 18.04 kg, representing a 17.21% decrease from baseline.”
Humanspatients with obesitymedian 7.5 mg6 monthsn = 107
Clinical nutrition ESPEN
Tirzepatide is linked with lower body weight in type 1 diabetes and obesity (13.4 kg [11.0, 15.8]).
“weight (13.4 kg [11.0, 15.8], p < 0.001) and total daily insulin dose (29.9 units [16.9, 42.9], p < 0.001).”
Humansin type 1 diabetes and obesity5 mg weekly12 months
Diabetes, obesity & metabolism
Tirzepatide is linked with lower body weight in humans (combined with lifestyle modification) (-3.73±2.44 kg after 12 weekly doses).
“with BMI (kg/m2), weight (kg), WC (cm), FBS (mg/dL), and PPBS (mg/dL) decreasing by 1.16±0.90, 3.73±2.44, 2.19±0.27, 22.34±24.69, and 52.63±48.02 after 12 weekly doses”
Humanscombined with lifestyle modification12 weekly dosesn = 21
ADA Scientific Sessions 2026 abstract
All 11Fewer
Apnea-hypopnea index
downin humans5downin reviews1
6 studies
Apnea-hypopnea index
downin humans5downin reviews1
Tirzepatide decreases apnea-hypopnea index in humans (compared with placebo, across baseline subgroups) (-27.7 to -34.1 events/h by baseline age subgroup).
“Participants treated with tirzepatide experienced reductions in AHI across subgroups, regardless of baseline age (-27.7 to -34.1 events/h), sex (-19.8 to -32.6 events/h)”
Human trialcompared with placebo, across baseline subgroupsmaximum tolerated dose (10 mg or 15 mg)52 weeks
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Tirzepatide decreases apnea-hypopnea index in humans.
“In both studies, tirzepatide treatment was associated with a greater reduction in AHI and SASHB than placebo, regardless of baseline age.”
Human trial52 weeks
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Tirzepatide decreases apnea-hypopnea index in humans (MD -21.85 events/h, 95% CI [-27.52, -16.34]).
“The NMA results suggested that tirzepatide ranking highest of producing the greatest AHI reduction (MD = -21.85 events/h, 95 % CI [-27.52, -16.34])”
Human trial
Respiratory medicine
Tirzepatide decreases apnea-hypopnea index in humans (obstructive sleep apnea with concurrent obesity).
“tirzepatide produced randomized, placebo-controlled reductions in the apnea-hypopnea index, sleep apnea-specific hypoxic burden, body weight, and systemic inflammation.”
Reviewobstructive sleep apnea with concurrent obesity
Multidisciplinary respiratory medicine
Tirzepatide decreases apnea-hypopnea index in humans (obstructive sleep apnea; compared with placebo) (MD −21.96 events/h; 95% CI, −26.16 to −17.76).
“tirzepatide (MD −21.96 events/h; 95% CI, −26.16 to −17.76) demonstrated the highest efficacy in AHI reduction.”
Reviewobstructive sleep apnea; compared with placebo
Frontiers in neurology
Tirzepatide decreases apnea-hypopnea index (obesity-related OSA).
“Incretin-based therapies, particularly tirzepatide, have emerged as promising treatments for obesity-related OSA following the SURMOUNT-OSA trial, demonstrating significant reductions in apnea–hypopnea index”
Reviewobesity-related OSA
Management of Obstructive Sleep Apnea in People with Type 2 Diabetes
Diabetology
Tirzepatide decreases apnea-hypopnea index in humans (moderate to severe obstructive sleep apnea and obesity).
“In patients with moderate to severe OSA and obesity, tirzepatide reduced the apneahypopnea index”
Reviewmoderate to severe obstructive sleep apnea and obesity
Meditsinskiy sovet = Medical Council
C-reactive protein
downin humans6
6 studies
C-reactive protein
downin humans6
Tirzepatide decreases C-reactive protein in humans (vs placebo plus lifestyle modification) (-55.1% and -65.3% vs -17.7%).
“reduced leptin (-57.3% and -63.1% vs -8.4%), high-sensitivity C-reactive protein (-55.1% and -65.3% vs -17.7%)”
Human trialvs placebo plus lifestyle modification10 or 15 mg72 weeks
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Tirzepatide decreases C-reactive protein in obese patients undergoing transfemoral TAVR (marked reduction, not quantified).
“Tirzepatide was associated with marked reductions in CRP and body weight”
Human trialin obese patients undergoing transfemoral TAVR
Cardiovascular revascularization medicine : including molecular interventions
Tirzepatide is linked with lower C-reactive protein in humans (concurrent with biologic therapy in obese psoriatic arthritis) (4.2±3.8 vs 7.7±3.0 mg/L).
“and lower CRP (4.2±3.8 vs 7.7±3.0 mg/L, p<0.001).”
Humansconcurrent with biologic therapy in obese psoriatic arthritis2.5 mg/week uptitrated to 5 mg/week6 months
RMD open
Tirzepatide is linked with lower C-reactive protein in Indian patients with obesity (declined 30-43%).
“hs-CRP declined 30-43% (p<0.0001).”
Humansin Indian patients with obesity24 weeksn = 91
ADA Scientific Sessions 2026 abstract
Tirzepatide decreases C-reactive protein in humans (29–55% reduction).
“lowers high-sensitivity C-reactive protein (hsCRP) by 29–55% across randomised trials in obesity, heart failure with preserved ejection fraction and obstructive sleep apnoea”
ReviewTrials in obesity, heart failure with preserved ejection fraction, and obstructive sleep apnea
Reviews in endocrine & metabolic disorders
Tirzepatide decreases C-reactive protein in humans (Compared with placebo or standard of care; six studies) (-34.3% (95% CI -38.4% to -30.1%)).
“Tirzepatide significantly reduced hsCRP by 34.3% (95% CI: -38.4% to -30.1%; P < .0001; I2 = 0.0%; 6 studies)”
ReviewCompared with placebo or standard of care; six studies
The Journal of clinical endocrinology and metabolism
Lean mass
downin humans4downin reviews1−11% lean mass
5 studies
Lean mass
downin humans4downin reviews1−11% lean mass
Tirzepatide decreases lean mass in humans (overweight or obesity).
“The publications examined indicated that treatment with semaglutide and tirzepatide may promote reductions in both fat mass and lean mass.”
Reviewoverweight or obesity
Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
Tirzepatide decreases lean mass in humans (SURMOUNT-1 body composition substudy) (10.9% reduction in lean mass).
“participants treated with tirzepatide showed mean reductions of 21.3% in body weight, 33.9% in fat mass and 10.9% in lean mass over 72 weeks”
ReviewSURMOUNT-1 body composition substudy72 weeks
Tirzepatide, body composition and risk of sarcopenia: a critical narrative review
LUMEN ET VIRTUS
Tirzepatide decreases lean mass in humans (obesity; SURMOUNT-1 substudy) (10.9% reduction in lean mass).
“tirzepatide promoted reductions of 21.3% in body weight, 33.9% in fat mass, and 10.9% in lean mass over 72 weeks.”
Reviewobesity; SURMOUNT-1 substudy72 weeks
Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida
Tirzepatide decreases lean mass.
“although a reduction in lean mass may also occur.”
Review
Aposta
Tirzepatide decreases lean mass in humans.
“A similar trend has been described in patients treated with tirzepatide.”
Review
Biomedicine Advances
Gastrointestinal adverse events
no changein humans3upin humans2+59%
5 studies
Gastrointestinal adverse events
no changein humans3upin humans2+59%
Tirzepatide increases gastrointestinal adverse events in humans (compared with dulaglutide) (2827 patients (42.5%) vs 2387 patients (35.9%)).
“Gastrointestinal adverse events were more common with tirzepatide (2827 patients [42.5%]) than dulaglutide (2387 patients [35.9%]) treatment.”
Human trialcompared with dulaglutideup to 15 mg weeklymedian 46.9 monthsn = 13,165
JAMA cardiology
Tirzepatide was not clearly linked with gastrointestinal adverse events in humans (landmark target trial emulation).
“Rates of expected gastrointestinal adverse events were comparable between groups.”
Humanslandmark target trial emulation2 yearsn = 1,594
ESC Congress 2026 abstract
Tirzepatide is linked with higher gastrointestinal adverse events in humans (real-world retrospective cohort, 3-month follow-up) (59.2%).
“Gastrointestinal adverse events were common (59.2%) but predominantly mild to moderate.”
Humansreal-world retrospective cohort, 3-month follow-up3 monthsn = 71
ADA Scientific Sessions 2026 abstract
Tirzepatide was not clearly linked with gastrointestinal adverse events in humans (compared with semaglutide).
“Gastrointestinal AEs did not differ between the two groups.”
Humanscompared with semaglutide
Diabetes technology & therapeutics
Tirzepatide showed no clear effect on gastrointestinal adverse events in humans (versus semaglutide) (risk ratio 1.08, 95% CI 0.97-1.20).
“Rates of gastrointestinal adverse events were comparable between groups (risk ratio 1.08, 95% CI 0.97-1.20)”
Reviewversus semaglutide
ADA Scientific Sessions 2026 abstract
Fat mass
downin humans3downin reviews2−34% fat mass
5 studies
Fat mass
downin humans3downin reviews2−34% fat mass
Tirzepatide is linked with lower fat mass in humans (combined with a standardized low-carbohydrate diet and tailored physical activity) (-35%).
“Fat mass (FM) largely reduced by 35%, fat-free mass slightly decreased by 5% (p < 0.001 for both)”
Humanscombined with a standardized low-carbohydrate diet and tailored physical activityinitiated at 2.5 mg once weekly, increased to 5 mg; mean 5.32 mg24 weeksn = 122
Journal of diabetes and its complications
Tirzepatide decreases fat mass in humans (SURMOUNT-1 body composition substudy) (33.9% reduction in fat mass).
“participants treated with tirzepatide showed mean reductions of 21.3% in body weight, 33.9% in fat mass and 10.9% in lean mass over 72 weeks”
ReviewSURMOUNT-1 body composition substudy72 weeks
Tirzepatide, body composition and risk of sarcopenia: a critical narrative review
LUMEN ET VIRTUS
Tirzepatide decreases fat mass.
“most of the weight loss associated with tirzepatide corresponds to a reduction in fat mass, including visceral and ectopic fat”
Review
Aposta
Tirzepatide decreases fat mass (obesity treatment).
“Semaglutide and tirzepatide preferentially reduce fat mass, including visceral and ectopic adiposity, while producing smaller but consistent reductions in lean mass or lean soft tissue.”
Reviewobesity treatment
Metabolites
Tirzepatide decreases fat mass in individuals with overweight and obesity.
“mainly through a reduction in fat mass.”
Reviewin individuals with overweight and obesity
Effects of tirzepatide on weight loss and body composition: clinical and functional implications
Revista Ibero-Americana de Humanidades, Ciências e Educação
Triglyceride
downin humans4
4 studies
Triglyceride
downin humans4
Tirzepatide decreases triglyceride in a patient with severe hypertriglyceridemia and type 2 diabetes (from 335 mg/dL to 85 mg/dL at 12 months).
“triglycerides normalized to 137 mg/dL at 3 months and 85 mg/dL at 12 months”
Human trialin a patient with severe hypertriglyceridemia and type 2 diabetes12 monthsfemalesn = 1
Cardiovascular diabetology. Endocrinology reports
Tirzepatide decreases triglyceride in humans (versus liraglutide).
“All tirzepatide doses were associated with statistically greater improvements in triglycerides and diastolic blood pressure versus liraglutide”
Human trialversus liraglutide5, 10 and 15 mg
Advances in therapy
Tirzepatide is linked with lower triglyceride in humans (real-world retrospective cohort, 3-month follow-up) (−46.4 mg/dL).
“Significant improvements were observed in systolic blood pressure (−5.6 mmHg), triglycerides (−46.4 mg/dL)”
Humansreal-world retrospective cohort, 3-month follow-up3 monthsn = 71
ADA Scientific Sessions 2026 abstract
Tirzepatide is linked with lower triglyceride in humans (compared with liraglutide and semaglutide groups) (greater reduction than in the other groups).
“Improvements in lipid parameters were observed across all groups, with greater triglyceride reduction in the tirzepatide group.”
Humanscompared with liraglutide and semaglutide groups36 weeks
Diabetes, metabolic syndrome and obesity : targets and therapy
6-minute walk distance
upin humans3
3 studies
6-minute walk distance
upin humans3
Tirzepatide improves 6-minute walk distance in humans (at 52 weeks) (+18 (95% CI 5, 31) m for women vs +15 (95% CI −2, 31) m for men).
“There were no differences by sex in the effect of tirzepatide on 6MWD at 52 weeks (+18 (95% CI 5, 31) m for women vs +15 (95% CI −2, 31) m for men, interaction p=0.761).”
Human trialat 52 weeks5 mg to 15 mg/weekn = 731
JACC. Heart failure
Tirzepatide is linked with better 6-minute walk distance in humans (obesity-related HFpEF, prospective real-world cohort) (+43 m).
“6-min walk distance by +43 m (q < 0.001)”
Humansobesity-related HFpEF, prospective real-world cohortmedian follow-up 5.8 monthsn = 50
International journal of cardiology
Tirzepatide improves 6-minute walk distance in humans (SUMMIT trial) (+15.8 m).
“In the SUMMIT trial, KCCQ-CSS improved by 5.1 points (P < .001) and 6 MWT by 15.8 m (P = .004).”
ReviewSUMMIT trial
The Journal of clinical endocrinology and metabolism
Cardiometabolic risk factors
downin humans2upin humans1
3 studies
Cardiometabolic risk factors
downin humans2upin humans1
Tirzepatide decreases cardiometabolic risk factors in humans.
“favourable treatment differences in cardiometabolic risk factors and quality-of-life measures in adults ≥ 65 years”
Human trial
Diabetes, obesity & metabolism
Tirzepatide decreases cardiometabolic risk factors in humans (obstructive sleep apnea and obesity; compared with placebo).
“tirzepatide treatment was associated with greater alleviation of cardiometabolic risk factors than placebo.”
Human trialobstructive sleep apnea and obesity; compared with placebo52 weeks
Nature medicine
Tirzepatide improves cardiometabolic risk factors in humans.
“Tirzepatide also improved cardiometabolic risk factors, body composition, physical functioning, and health-related quality of life.”
Review
Cureus
Body mass index
downin humans3
3 studies
Body mass index
downin humans3
Tirzepatide decreases body mass index in participants who shifted to a lower BMI category (-8.90 vs -3.65 kg/m2 (SURMOUNT-1); -10.47 vs -5.20 kg/m2 (SURMOUNT-4)).
“Among these participants, mean BMI reductions were greater than in those without improvement (SURMOUNT-1: -8.90 vs -3.65 kg/m2; SURMOUNT-4: -10.47 vs -5.20 kg/m2).”
Human trialin participants who shifted to a lower BMI category72 weeks (SURMOUNT-1); 88 weeks (SURMOUNT-4)
American journal of preventive cardiology
Tirzepatide is linked with lower body mass index in humans (concurrent with biologic therapy in obese psoriatic arthritis) (-2.9±2.0 vs +0.4±1.2 kg/m2).
“The tirzepatide group showed greater BMI reduction (-2.9±2.0 vs +0.4±1.2 kg/m2, p<0.001)”
Humansconcurrent with biologic therapy in obese psoriatic arthritis2.5 mg/week uptitrated to 5 mg/week6 months
RMD open
Tirzepatide decreases body mass index in humans (-1.2 kg/m2 absolute reduction (95% CI -5.9 to -1.1)).
“body mass index of -1.2 kg/m2 (95% CI: -5.9 to -1.1)”
Reviewpooled across four non-randomized observational studies in solid organ transplant recipients
Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis
Frontiers in pharmacology
Serious adverse events
no changein humans2
2 studies
Serious adverse events
no changein humans2
Tirzepatide showed no clear effect on serious adverse events in humans (odds ratio 0.98 (95% CI 0.82 to 1.17)).
“or SAEs (odds ratio 0.98, 95% CI 0.82 to 1.17; p = 0.80; 21 trials”
Human trialplacebo-controlled trials in patients at increased risk of cardiovascular events; 21 trials
BMC medicine
Tirzepatide showed no clear effect on serious adverse events in humans (Overweight or obesity; versus placebo).
“The risks of developing any serious AEs with the use of tirzepatide, semaglutide, orlistat, and sibutramine were not statistically different from those with placebo.”
ReviewOverweight or obesity; versus placebo
Terapevticheskii arkhiv
Predicted 10-year cardiovascular disease risk
downin humans2HR 0.77
2 studies
Predicted 10-year cardiovascular disease risk
downin humans2HR 0.77
Tirzepatide decreases predicted 10-year cardiovascular disease risk in humans (Difference versus placebo −2.4 percentage points (95% CI −3.4 to −1.4); estimated HR 0.77 (95% CI 0.69–0.85)).
“After 112 weeks, TZP MTD was associated with a significant reduction in predicted 10-year CVD risk when compared to switching to placebo”
Human trialObesity or overweight without diabetes or baseline cardiovascular disease; continued maximum tolerated dose versus switching to placebo after 60 weeks of tirzepatide10 mg or 15 mg once weekly112 weeks, including 52 weeks of randomized maintenancen = 133
AHA Scientific Sessions 2026 abstract
Tirzepatide decreases predicted 10-year cardiovascular disease risk in humans (people with obesity/overweight and prediabetes, SURMOUNT-1 post hoc analysis) (ARR -1.92% at week 72).
“receiving tirzepatide 15 mg was associated with a reduction in the predicted 10-year CVD risk at week 72 (absolute risk reduction, (ARR) -1.92%)”
Human trialpeople with obesity/overweight and prediabetes, SURMOUNT-1 post hoc analysis15 mg72 weeksn = 962
European journal of preventive cardiology
All 289Fewer
What is tirzepatide linked with?
196Studies link tirzepatide with 196 measures, among them body weight, mortality and major adverse cardiovascular events.
Body weight
downin humans18downin reviews1
19 studies
Body weight
downin humans18downin reviews1
Tirzepatide is associated with body weight in humans (Normoglycemic individual treated for weight loss).
“Tirzepatide exposure was associated with rapid weight loss in a normoglycaemic individual.”
HumansNormoglycemic individual treated for weight lossmalesn = 1
Journal of the peripheral nervous system : JPNS
Tirzepatide is associated with body weight in humans (60.7% reported >10% weight reduction).
“60.7% had achieved >10% reduction”
HumansParticipants with psoriasis and obesity/overweight taking concomitant ixekizumab and tirzepatide; self-reported change since starting tirzepatide82.0% femalesn = 89
Skin (Milwood, N.Y.)
Tirzepatide is associated with body weight in humans (obesity) (Median weight loss 8.3% at 3 months and 15.0% at 6 months).
“Median weight loss was 8.3% and 15.0% at 3 and 6 months, respectively.”
Humansobesity6 monthsn = 76
Obesity research & clinical practice
Tirzepatide is associated with body weight in humans (Obesity without diabetes) (30.4% achieved ≥5% total body weight loss; 22.5% achieved ≥10%).
“corresponding rates were 30.4% and 22.5% among tirzepatide initiators.”
HumansObesity without diabetesInjectable12 monthsn = 296,817
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with body weight in humans (Switching from semaglutide to tirzepatide versus continuing semaglutide) (3.0 kg greater weight reduction (95% CI, 1.2–5.0)).
“switching to tirzepatide produced greater weight reduction than continuing semaglutide (difference of 3.0 kg, 95% CI, 1.2–5.0)”
HumansSwitching from semaglutide to tirzepatide versus continuing semaglutide2 years after target trial emulation enrollmentn = 15,154
EClinicalMedicine
Tirzepatide is associated with body weight in humans (Body weight −11.22 kg (10.4%); fat mass −7.90 kg (16.8%); BIA-derived fat-free mass −3.35 kg (5.4%)).
“Estimated marginal body weight fell by 11.22 kg (10.4%), fat mass by 7.90 kg (16.8%), and BIA-derived FFM by 3.35 kg (5.4%) at 12 weeks”
Humansadults with obesity receiving tirzepatide monotherapy; available-data, on-treatment estimates12 weeks66% females
Journal of clinical medicine
Tirzepatide is associated with body weight in humans (Compared with dulaglutide in breast cancer patients receiving concurrent endocrine therapy) (-4.7% versus +0.1% with dulaglutide; overall agent comparison p = 0.003).
“semaglutide (- 5.8%) and tirzepatide (- 4.7%) outperformed dulaglutide (+ 0.1%)”
HumansCompared with dulaglutide in breast cancer patients receiving concurrent endocrine therapyOne year
Breast cancer research and treatment
Tirzepatide is associated with body weight in humans (obesity; unsupervised use) (15 kg weight loss).
“self-administered tirzepatide, lost 15 kg over about 3 months”
Humansobesity; unsupervised useabout 3 monthsmalesn = 1
Frontiers in endocrinology
Tirzepatide is associated with body weight in humans (Obesity) (11 kg in the man and 9 kg in the woman).
“At 3 months, body weight had decreased by 11 kg and 9 kg, respectively.”
HumansObesityStarting at 2.5 mg once weekly for 4 weeks, titrated up to 10 mg weekly3 monthsBothsn = 2
Preprints.orgPreprint
Tirzepatide is associated with body weight in humans (Chronic kidney disease stages 1–5, type 2 diabetes mellitus and obesity) (Median weight 103 to 100 kg; p < 0.0001).
“Tirzepatide significantly reduced median weight (103-100 kg; p < 0.0001), HbA1c (63 [7.9%] to 54 [7.1%] mmol/mol; p = 0.002)”
HumansChronic kidney disease stages 1–5, type 2 diabetes mellitus and obesityMedian 21.4 weeksn = 62
Diabetic medicine : a journal of the British Diabetic Association
All 19Fewer
Mortality
downin humans19HR 0.1–0.8
19 studies
Mortality
downin humans19HR 0.1–0.8
Tirzepatide is associated with mortality in humans (3-year HR 0.67 (95% CI 0.46–0.98)).
“All-cause mortality was lower with TZP at 3years (HR 0.67, 0.46-0.98, p=0.04).”
HumansNon-diabetic adults with obesity and established atherosclerotic cardiovascular disease; compared with semaglutide3 years
Tirzepatide linked to more atrial fibrillation than semaglutide
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with mortality in humans (Type 2 diabetes; compared with metformin) (1-year HR 0.344; RR 0.302; all p<0.0001).
“tirzepatide (1-year: RR 0.302, HR 0.344; extended [364 vs 730 days]: RR 0.220, HR 0.466; all p<0.0001)”
HumansType 2 diabetes; compared with metformin1 year
Diabetes drugs linked to fewer deaths in young adults
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with mortality in humans (PCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide) (0.2% vs 1.5%; HR 0.10, 95% CI 0.02–0.40).
“Tirzepatide use was associated with lower five-year hazards of all-cause mortality (0.2% vs 1.5%; HR, 0.10; 95% CI, 0.02 - 0.40; p<0.01)”
HumansPCOS and T2DM receiving metformin; propensity-matched comparison with no tirzepatide5 yearsfemalesn = 4,345
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with mortality in humans (Adults with serious mental illness; compared with SGLT2 inhibitors) (RR 0.27; P<.0001).
“Mortality reductions were driven by semaglutide (RR 0.55) and tirzepatide (RR 0.27; P<.0001)”
HumansAdults with serious mental illness; compared with SGLT2 inhibitors
Diabetes drugs linked to fewer deaths in serious mental illness
AHA Scientific Sessions 2026 abstract
Tirzepatide is linked with a lower risk of mortality in humans (HR 0.38 (95% CI 0.25–0.58)).
“all-cause mortality (HR, 0.38; 95% CI, 0.25–0.58)”
Humansin adults with obesity and major depressive disorder, compared with non-GLP-1RA anti-obesity medicationsn = 24,103
Translational psychiatry
Tirzepatide is associated with mortality in humans (Stage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide) (1-year HR 0.75; 3-year HR 0.78).
“tirzepatide was associated with lower cardiovascular and renal event rates than semaglutide, with comparable safety.”
HumansStage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide3 years
Clinical Medicine Insights. Cardiology
Tirzepatide is associated with mortality in humans (HR 0.55, 95% CI 0.42–0.72).
“Outcomes were similar between TZP and GLP-1RA, except TZP showed lower mortality (HR 0.55 [95% CI 0.42-0.72]).”
HumansCoexisting COPD and type 2 diabetes; compared with other glucagon-like peptide-1 receptor agonistsDay 1 through day 365n = 6,727
Tirzepatide linked to fewer chronic lung disease flare-ups
Frontiers in pharmacology
Tirzepatide is associated with mortality in humans (Patients with type 2 diabetes; compared with semaglutide) (0.6% vs. 0.9%; ARD -0.3% (95% CI -0.33 to -0.24); HR 0.8 (95% CI 0.74–0.84)).
“all-cause mortality (0.6% vs. 0.9%; ARD - 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84)”
HumansPatients with type 2 diabetes; compared with semaglutide
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
Journal of diabetes and metabolic disorders
Tirzepatide is linked with a lower risk of mortality in humans (compared with semaglutide in patients with obesity) (HR 0.8).
“The tirzepatide group were also at lower risk of all-cause mortality (HR, 95% CI: 0.8, 0.77─0.91)”
Humanscompared with semaglutide in patients with obesityone yearn = 424,269
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide
medRxivPreprint
Tirzepatide is linked with a lower risk of mortality in humans (versus GLP-1 receptor agonists) (HR 0.69, 95% CI 0.59-0.80).
“Tirzepatide was associated with lower risks of mortality (HR 0.69, 95% CI 0.59-0.80), periodontitis (0.70, 0.57-0.86), tooth extraction (0.89, 0.84-0.94), peri-implant complications (0.61, 0.52-0.70)”
Humansversus GLP-1 receptor agonists1-year follow-upn = 97,993
Diabetes research and clinical practice
All 19Fewer
Major adverse cardiovascular events
downin humans10RR 0.339–0.56
10 studies
Major adverse cardiovascular events
downin humans10RR 0.339–0.56
Tirzepatide is associated with major adverse cardiovascular events in humans (Type 2 diabetes; compared with metformin) (RR 0.339–0.433; HR 0.429–0.566; p<0.0001).
“with larger reductions for tirzepatide vs metformin (RR 0.339-0.433, HR 0.429-0.566; p<0.0001; 385 vs 521 days)”
HumansType 2 diabetes; compared with metformin2 years
Diabetes drugs linked to fewer deaths in young adults
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with major adverse cardiovascular events in humans (elevated lipoprotein(a)) (HR 0.72; 95% CI, 0.58-0.89).
“tirzepatide use was associated with a lower hazard of MACE (HR 0.72; 95% CI, 0.58-0.89)”
Humanselevated lipoprotein(a)2 years
Tirzepatide Use and Major Adverse Cardiovascular Events Among Patients with Elevated Lipoprotein(a)
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with major adverse cardiovascular events in humans (4.2% vs 7.4%; RR 0.56, 95% CI 0.38–0.83).
“MACE (4.2% vs 7.4%; RR, 0.56; 95% CI, 0.38-0.83; p<0.05)”
HumansPatients with obesity undergoing atrial fibrillation catheter ablation; at least 1 month of prior tirzepatide use90 days to 2 years post-ablationn = 1,772
AHA Scientific Sessions 2026 abstract
Tirzepatide is associated with major adverse cardiovascular events in humans (Stage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide) (3-year HR 0.84, 95% CI 0.78–0.91; risk difference -1.09 per 1,000 patients).
“Compared with semaglutide, tirzepatide was associated with lower rates of major adverse cardiovascular events”
HumansStage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide3 years
Clinical Medicine Insights. Cardiology
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (compared with sitagliptin as a placebo proxy) (HR 0.68 (95% CI 0.58 to 0.80); risk difference -1.4% (95% CI -2.1% to -0.7%); NNT=70).
“initiating tirzepatide reduced the risk of MACE compared with a placebo proxy among people with type 2 diabetes and established atherosclerotic cardiovascular disease”
Humanscompared with sitagliptin as a placebo proxyup to one yearn = 52,971
Tirzepatide is linked to lower risk of major heart events
BMJ (Clinical research ed.)
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (versus dulaglutide, 1-year follow-up) (HR 0.89 (95% CI 0.84–0.93) at 1 year).
“MACE (HR: 0.89, 95% [CI: 0.84-0.93])”
Humansversus dulaglutide, 1-year follow-up1 year
Clinical cardiology
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (versus dulaglutide initiators) (HR 0.80, 95% CI 0.65-0.99).
“Tirzepatide initiators experienced a lower rate of modified MACE versus dulaglutide initiators (IR 31.3 vs. 39.4, respectively; HR 0.80 [95% CI 0.65-0.99])”
Humansversus dulaglutide initiators
Diabetes care
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (compared with SGLT2 inhibitors in adults with MASLD) (HR 0.68 (95% CI 0.58-0.80)).
“TZP was also associated with lower risks of all-cause mortality (HR, 0.55; 95% CI, 0.43-0.71), MACEs (HR, 0.68; 95% CI, 0.58-0.80), and MALOs (HR, 0.66; 95% CI, 0.54-0.80).”
Humanscompared with SGLT2 inhibitors in adults with MASLDn = 23,106
Hepatology international
Tirzepatide is associated with major adverse cardiovascular events in humans (Type 2 diabetes without baseline dementia; versus SGLT2 inhibitors).
“Tirzepatide and semaglutide reduced MACE vs SGLT2-i.”
HumansType 2 diabetes without baseline dementia; versus SGLT2 inhibitors2 yearsn = 14,462
Diabetes research and clinical practice
Tirzepatide lowers the risk of major adverse cardiovascular events in humans (class-level analysis versus placebo) (HR 0.79, 95% CI 0.69-0.91).
“tirzepatide significantly reduced MACE (HR 0.79, 95% CI 0.69-0.91)”
Reviewclass-level analysis versus placebo
Cardiovascular diabetology
Type 2 diabetes
downin humans3
3 studies
Type 2 diabetes
downin humans3
Tirzepatide lowers the risk of type 2 diabetes in humans (stratified by glycemic high-risk criteria, compared with placebo) (90% to 99% reduction in high-risk groups; 68% to 91% in standard-risk groups).
“Tirzepatide treatment was associated with a 90% to 99% reduction in new-onset T2D in the high-risk groups, vs 68% to 91% in the standard risk groups”
Human trialstratified by glycemic high-risk criteria, compared with placebo3-year
Journal of the Endocrine Society
Tirzepatide lowers the risk of type 2 diabetes in humans.
“Tirzepatide treatment was associated with a significant reduction in incident T2D compared with placebo in 5 out of 6 glycemic risk subgroups shown in.”
Human trial176 weeksn = 1,032
Journal of the Endocrine Society
Tirzepatide lowers the risk of type 2 diabetes in humans (compared with semaglutide).
“a lower incidence of new-onset type 2 diabetes”
Reviewcompared with semaglutide
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Cureus
Tirzepatide lowers the risk of type 2 diabetes in the prediabetes subgroup of SURMOUNT-1.
“Zepbound also reduced progression to type 2 diabetes mellitus (T2DM) through 176 weeks”
Reviewin the prediabetes subgroup of SURMOUNT-1through 176 weeks
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
Heart failure
downin humans3HR 0.66–0.75
3 studies
Heart failure
downin humans3HR 0.66–0.75
Tirzepatide lowers the risk of heart failure in women and men (HR 0.66 (95% CI 0.38, 1.18) for women, 0.61 (95% CI 0.33, 1.13) for men).
“There was no heterogeneity in the effect of tirzepatide on the primary outcome of worsening HF or cardiovascular death by sex (HR 0.66 (95% CI 0.38, 1.18) for women, 0.61 (95% CI 0.33, 1.13) for men, treatment*sex interaction p=0.813; ).”
Human trialin women and menn = 731
JACC. Heart failure
Tirzepatide lowers the risk of heart failure in humans (obesity-related HFpEF) (HR: 0.66).
“The effect of tirzepatide on the risk of worsening HF or cardiovascular death did not differ in women and men (HR: 0.66 and 0.61, respectively, interaction P = 0.81)”
Human trialobesity-related HFpEF52 weeksfemalesn = 393
JACC. Heart failure
Tirzepatide lowers the risk of heart failure in humans (compared with placebo, network meta-analysis) (OR 0.55 (95% CI 0.33-0.92)).
“sotagliflozin (OR 0.50; 0.36-0.69; p-score=0.87), and tirzepatide (OR 0.55; 95% CI 0.33-0.92; p-score=0.80), had lowest odds of HF”
Human trialcompared with placebo, network meta-analysis
ADA Scientific Sessions 2026 abstract
Tirzepatide lowers the risk of heart failure in humans (subgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists) (HR 0.75, 95% CI 0.58-0.97).
“In exploratory subgroup analyses, patients with type 2 diabetes showed lower estimated risks of all-cause mortality (HR 0.85, 95% CI 0.76-0.94) and heart failure (HR 0.75, 95% CI 0.58-0.97).”
Reviewsubgroup of patients with type 2 diabetes compared with GLP-1 receptor agonists
Diabetes, obesity & metabolism
Myocardial infarction
downin humans2upin humans1HR 0.67–1.26
3 studies
Myocardial infarction
downin humans2upin humans1HR 0.67–1.26
Tirzepatide is associated with myocardial infarction in humans (5-year HR 1.26 (95% CI 1.12–1.42)).
“MI risk was modestly elevated (5-year HR 1.26, 1.12-1.42, p=0.0002).”
HumansNon-diabetic adults with obesity and established atherosclerotic cardiovascular disease; compared with semaglutide5 years
Tirzepatide linked to more atrial fibrillation than semaglutide
AHA Scientific Sessions 2026 abstract
Tirzepatide is linked with a lower risk of myocardial infarction in humans.
“tirzepatide demonstrated the largest observed association with reduced recurrent MI risk, followed by semaglutide.”
Humans5-year
AHA Scientific Sessions 2026 abstract
Tirzepatide is linked with a lower risk of myocardial infarction in humans (compared with sitagliptin as a placebo proxy) (HR 0.67 (95% CI 0.52 to 0.87); NNT=130).
“tirzepatide was associated with a lower hazard for myocardial infarction (hazard ratio 0.67, 0.52 to 0.87; NNT=130)”
Humanscompared with sitagliptin as a placebo proxyup to one yearn = 52,971
Tirzepatide is linked to lower risk of major heart events
BMJ (Clinical research ed.)
Stroke
downin humans3RR 0.71
3 studies
Stroke
downin humans3RR 0.71
Tirzepatide is linked with a lower risk of stroke in humans (compared with other glp-1 receptor agonists) (absolute difference in stroke risk 2.1 percentage points at one year).
“tirzepatide use was associated with lower risks of any stroke, ischemic stroke, hemorrhagic stroke, and death from any cause”
Humanscompared with other glp-1 receptor agonistsone year
Nature communications
Tirzepatide lowers the risk of stroke in humans (Type 2 diabetes with established or high-risk cardiovascular disease; versus placebo) (RR 0.71; 95% CI 0.54–0.93).
“Stroke was significantly reduced by tirzepatide (RR 0.71; 0.54-0.93)”
ReviewType 2 diabetes with established or high-risk cardiovascular disease; versus placebo
AHA Scientific Sessions 2026 abstract
Tirzepatide lowers the risk of stroke in humans (versus placebo, network meta-analysis).
“Dulaglutide 1.5 mg and tirzepatide 15 mg significantly reduced stroke risk.”
Reviewversus placebo, network meta-analysis15 mg
Diabetes, obesity & metabolism
Atrial fibrillation
downin humans2upin humans1HR 0.41–1.04
3 studies
Atrial fibrillation
downin humans2upin humans1HR 0.41–1.04
Tirzepatide is associated with atrial fibrillation in humans (Patients with obesity without prior atrial fibrillation; compared with bariatric surgery) (HR 0.41, 95% CI 0.30–0.57; incidence 0.2% vs 0.6%; RD −0.4%).
“Tirzepatide was associated with lower AF incidence compared with bariatric surgery (0.2% vs 0.6%; HR 0.41, 95% CI 0.30-0.57; RD –0.4%; p<0.001)”
HumansPatients with obesity without prior atrial fibrillation; compared with bariatric surgery3 yearsn = 19,759
AHA Scientific Sessions 2026 abstract
Tirzepatide is linked with a lower risk of atrial fibrillation in humans (versus subcutaneous semaglutide, 1:1 propensity-matched, at 12 and 18 months) (HR 0.83–0.84 at both horizons).
“Significant reductions were also observed for incident AF (HR 0.83–0.84) and CKD progression (HR 0.82–0.84) at both horizons.”
Humansversus subcutaneous semaglutide, 1:1 propensity-matched, at 12 and 18 monthsn = 54,978
Research SquarePreprint
Tirzepatide is linked with a higher risk of atrial fibrillation in humans (versus dulaglutide, 1-year follow-up) (HR 1.04 (95% CI 1.00–1.07) at 1 year).
“Tirzepatide showed slightly higher 1-year atrial fibrillation risk (HR: 1.04, [1.00-1.07])”
Humansversus dulaglutide, 1-year follow-up1 year
Clinical cardiology
Major adverse cardiovascular events
downin humans3HR 0.6–0.8
3 studies
Major adverse cardiovascular events
downin humans3HR 0.6–0.8
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (landmark target trial emulation, 90 days to 2 years post-transplant) (HR 0.60, 95% CI 0.45–0.80).
“Kaplan–Meier cumulative incidence of MACE was 7.6% with tirzepatide versus 12.9% in controls”
Humanslandmark target trial emulation, 90 days to 2 years post-transplant2 yearsn = 1,594
ESC Congress 2026 abstract
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (HR 0.80 (95% CI 0.69–0.92) at 12 months; HR 0.84 (95% CI 0.75–0.94) at 18 months).
“Tirzepatide was associated with lower MACE at 12 months (hazard ratio [HR] 0.80; 95% CI 0.69–0.92)”
Humansversus subcutaneous semaglutide, 1:1 propensity-matched, 12-month landmark; 18-month HR 0.84 (95% CI 0.75–0.94)n = 54,978
Research SquarePreprint
Tirzepatide is linked with a lower risk of major adverse cardiovascular events in humans (compared with semaglutide, propensity-matched TriNetX cohort, 1-year follow-up) (3.7% vs 4.1%; RR 0.918 (95% CI 0.862-0.978)).
“Patients treated with tirzepatide experienced a significantly lower incidence of MACE”
Humanscompared with semaglutide, propensity-matched TriNetX cohort, 1-year follow-up1 yearn = 47,804
Diabetes & vascular disease research
HbA1c
downin humans3
3 studies
HbA1c
downin humans3
Tirzepatide is associated with HbA1c in humans (Japanese adults with type 2 diabetes mellitus) (Median HbA1c change -1.0 percentage point (-11 mmol/mol)).
“median HbA1c change was -1.0 percentage point (-11 mmol/mol)”
HumansJapanese adults with type 2 diabetes mellitusmaximum observed dose ≤5 mg/week28 weeksn = 37
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Tirzepatide is associated with HbA1c in humans (Stage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide).
“Mean HbA1c was modestly lower with tirzepatide.”
HumansStage 2 cardiovascular-kidney-metabolic syndrome; compared with semaglutide
Clinical Medicine Insights. Cardiology
Tirzepatide is associated with HbA1c in humans (Type 2 diabetes managed in secondary care) (HbA1c −17.7 mmol/mol; body weight −5.9 kg).
“Mean HbA1c decreased by 17.7 mmol/mol and body weight by 5.9 kg (both p<0.001).”
HumansType 2 diabetes managed in secondary careMean prescribed dose at follow-up: 5 mgMedian follow-up of 6.7 months51.9% femalesn = 295
Clinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes
TouchREVIEWS in endocrinology
Gastrointestinal adverse events
upin humans3+6.4% patients
3 studies
Gastrointestinal adverse events
upin humans3+6.4% patients
Tirzepatide raises the risk of gastrointestinal adverse events in humans (compared with dulaglutide).
“Gastrointestinal adverse events were common in both treatment groups but occurred more frequently with tirzepatide than dulaglutide.”
Human trialcompared with dulaglutidemedian (IQR) treatment duration of 46.9 (34.6-50.6) monthsn = 13,165
JAMA cardiology
Tirzepatide is associated with gastrointestinal adverse events in humans (real-world retrospective cohort) (6.4% of patients).
“Gastrointestinal adverse events occurred in 6.4% of patients”
Humansreal-world retrospective cohort52 weeksn = 203
Diabetes, obesity & metabolism
Tirzepatide is associated with gastrointestinal adverse events in humans (most common adverse events, generally mild to moderate).
“Gastrointestinal adverse events were the most common and were generally mild to moderate.”
Review
Cureus
MACE-4
downin humans2HR 0.78–0.81
2 studies
MACE-4
downin humans2HR 0.78–0.81
Tirzepatide lowers the risk of MACE-4 in humans (Type 2 diabetes and polyvascular cardiovascular disease; compared with dulaglutide) (HR 0.78 (95% CI 0.68–0.90), p<0.001).
“Risk of MACE-4 and one of its components, coronary revascularization, were reduced on tirzepatide in the polyvascular group”
Human trialType 2 diabetes and polyvascular cardiovascular disease; compared with dulaglutiden = 2,841
AHA Scientific Sessions 2026 abstract
Tirzepatide lowers the risk of MACE-4 in humans (HR 0.81, 95% CI 0.69–0.95).
“for MACE-4 0.81 (95%CI 0.69-0.95) and 0.91 (95%CI 0.83-1.00) in patients with and without HF, respectively.”
Human trialType 2 diabetes, atherosclerotic cardiovascular disease and history of heart failure; compared with dulaglutide 1.5 mg weeklyup to 15 mg weeklyaverage 4 years
European journal of preventive cardiology
Ischemic colitis
upin humans2
2 studies
Ischemic colitis
upin humans2
Tirzepatide is associated with ischemic colitis in a patient with type 2 diabetes, severe obesity, and cardiovascular comorbidities.
“This case highlights a potential association between tirzepatide therapy and ischemic colitis.”
Human trialin a patient with type 2 diabetes, severe obesity, and cardiovascular comorbiditiessecond dosefemales
Acute ischaemic colitis after initiation of tirzepatide in an elderly patient with type 2 diabetes
Emergency Care Journal
Tirzepatide is associated with ischemic colitis in humans (Preexisting ischemic colitis and multiple comorbidities).
“This case raises concern for a potential association between tirzepatide use and ischemic colitis in a patient with preexisting risk factors.”
HumansPreexisting ischemic colitis and multiple comorbiditiesinjectionfemales
Ischemic Colitis in the Setting of Tirzepatide Use: A Potentially Underrecognized Adverse Effect
Cureus
Concordance of predicted microbial functional effects
upin humans1
1 study
Concordance of predicted microbial functional effects
upin humans1
Tirzepatide is associated with concordance of predicted microbial functional effects in humans (comparison of tirzepatide and semaglutide in Type 2 diabetes) (Pearson r = 0.450; 67.1% concordant direction across 2106 predicted EC features; p < 0.001).
“Across 2106 predicted EC features, longitudinal effects were positively correlated between tirzepatide and semaglutide (67.1% concordant direction; Pearson r = 0.450, p < 0.001).”
Human trialcomparison of tirzepatide and semaglutide in Type 2 diabetes16 weeks
Diabetes, obesity & metabolism
Gut microbial genus trajectories
mixedin humans1
1 study
Gut microbial genus trajectories
mixedin humans1
Tirzepatide is associated with gut microbial genus trajectories in humans (Type 2 diabetes; versus conventional treatment) (q < 0.05).
“Longitudinal trajectories relative to the control group differed for several genera, including Romboutsia_B , Barnesiella and Ruminococcus_E with both treatments and Vescimonas with tirzepatide”
Human trialType 2 diabetes; versus conventional treatment16 weeks
Diabetes, obesity & metabolism
All 196Fewer
Has tirzepatide been tested in people?
73 of 181 about agingYes: 226 trials and 480 observational studies in people have been published, and 167 trials are registered.
About aging
Tirzepatide and Organ-specific Biological Aging
Phase 2Enrolling by invitation
Phase 4Recruiting
GLP-1s to Enhance Lasting Optimal Weight
Phase 4Active, not recruiting
Phase 3Active, not recruiting
Recruiting
Fighting Osteoporosis With Risedronate Co-Therapy During Incretin
Phase 3Not yet recruiting
All 40Fewer
Approved
FDA Mounjaro, Mounjaro Kwikpen, Mounjaro (Autoinjector)
May 13, 2022Diabetes Mellitus, Type 2, non-fatal myocardial infarction
Sep 15, 2022Diabetes Mellitus, Type 2, Obesity, Overweight, controlled type 2 diabetes mellitus
FDA Zepbound, Zepbound Kwikpen, Zepbound (Autoinjector)
Nov 8, 2023Obesity, Overweight, excess body weight, severe obstructive sleep apnea, moderate-to-severe obstructive sleep apnea
Repurposing
Phase 4Active, not recruiting10 trials
Phase 4Recruiting1 trial
Phase 4Recruiting1 trial
Phase 4Recruiting2 trials
Phase 4Recruiting4 trials
Phase 4Active, not recruiting1 trial
40 of 56Fewer
Every condition in trials
Fasting
Phase 4Completed1 trial
Motor Activity
Phase 3Results posted2 trials
Addictive Behavior
Phase 2Recruiting2 trials
Prostatic neoplasm
Phase 2Recruiting2 trials
Autosomal dominant polycystic kidney
Phase 2Recruiting1 trial
Biological aging
Phase 2Enrolling by invitation1 trial
All 10Fewer
Readouts due
- Nov 2026
Phase 3Active, not recruiting
- Nov 2026
Phase 3Active, not recruiting
- Nov 2026
- Dec 2026
- Dec 31, 2026
2024 Tirzepatide-Bariatric Surgery
Phase 4Recruiting
- Feb 14, 2027
All 21Fewer
Who is developing tirzepatide?
3 companies: Eli Lilly, Hudson Biotech and Novo Nordisk.
Trial sponsors
Company73 trialsPhase 467,197 people
Company2 trialsPhase 31,083 people
Company1 trialPhase 32,539 people
Company1 trialPhase 2285 people
Company1 trialPhase 2224 people
Company1 trialPhase 2204 people
Company1 trialPhase 2204 people
Company1 trialPhase 1/2190 people
Funding
11 grants since 2023National Institute of Diabetes and Digestive and Kidney Diseases$2.2MNational Institute on Alcohol Abuse and Alcoholism$396KNational Institute for Health Research£1M
Testing the effects of tirzepatide on colorectal cancer incidence and outcomes in a mouse model
National Cancer InstituteUniversity of Kansas Medical Center$399K2026–2028
Tirzepatide for treatment of familial partial lipodystrophy
National Institute of Diabetes and Digestive and Kidney DiseasesUniversity of Michigan at Ann Arbor$779K2025–2030
National Institute of Diabetes and Digestive and Kidney DiseasesMassachusetts General Hospital$719K2023–2029
National Institute of Allergy and Infectious DiseasesUniversity of Michigan at Ann Arbor$429K2026–2028
National Institute for Health ResearchUniversity of East Anglia£1M2026–2028
Phase II Evaluation of Tirzepatide in Adults with Alcohol Use Disorder and Overweight or Obesity
National Institute on Alcohol Abuse and AlcoholismUniversity of Southern California$185K2024–2026
National Institute on AgingNova Southeastern University$372K2024–2027
National Institute on Drug AbuseUniversity of Cincinnati$503K2024–2025
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary rewritten as its findings changed.
As it read before
Tirzepatide reduces cardiovascular and kidney events versus dulaglutide in a human trial; independent labs reproduce human weight and HbA1c reductions and mouse oxidative stress reductions, though some weight and HbA1c results differ. Eli Lilly funds work, sponsors trials and has author ties. Aging-related trials are registered; some trials across uses ended over a year ago without posted results.
Economic Burden of Obesity in Italy · 1 finding
Summary rewritten as its findings changed.
As it read before
Tirzepatide reduces cardiovascular and kidney outcomes versus dulaglutide in a human trial; independent labs reproduce human weight and HbA1c reductions, but some results show weight gain or no clear weight or HbA1c effect. There are 67 registered aging trials; four trials overall ended over a year ago without posted results. Developer Eli Lilly and Company funds papers and sponsors trials.
Summary rewritten as its findings changed.
As it read before
Human studies associate tirzepatide with lower mortality in type 2 diabetes with established atherosclerotic cardiovascular disease; independent labs reproduce weight and HbA1c reductions, but some studies report no change. Registrations include 42 aging-related trials; five trials across uses ended over a year ago without posted results or linked papers. Developer Eli Lilly funds work and sponsors trials, and authors declare ties to it.
Summary rewritten as its findings changed.
As it read before
A human trial reports lower combined cardiovascular and kidney risk with tirzepatide in type 2 diabetes with cardiovascular disease. Independent labs reproduce human HbA1c and weight reductions, but a human study reports no weight change. Of registered trials, 21 concern aging; five ended over a year ago without posted results or citing papers; developer Eli Lilly funds papers and sponsors trials.